Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.40 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979029 | 1.00 | PKM (0.60) | PKMHTTPOLBTSHRMEN1 | |
| SCHEMBL8790743 | 0.96 | PKM (0.55) | PKMHTTTSHRALDH1A1 | |
| SCHEMBL9340588 | 0.84 | PRMT5 (0.51) | PKMHTTPOLBTSHRMEN1 | |
| SCHEMBL2953774 | 0.84 | PRMT5 (0.51) | PKMHTTPOLBTSHRMEN1 | |
| SCHEMBL8115571 | 0.84 | PRMT5 (0.51) | PKMHTTPOLBTSHRMEN1 | |
| SCHEMBL31046060 | 0.84 | PRMT5 (0.51) | PKMHTTPOLBTSHRMEN1 | |
| SCHEMBL283634 | 0.80 | SLC12A2 (0.56) | POLBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2306082 | 0.80 | SLC12A2 (0.56) | POLBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL283635 | 0.80 | SLC12A2 (0.56) | POLBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL7070228 | 0.80 | PKM (0.42) | PKMHTTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | PKM 3316/4885HTT 3555/4885POLB 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.